KRT34 Antibody

What is KRT34 and what is its role in cellular biology?

KRT34 (keratin 34, also known as KRTHA4) is a member of the keratin family of proteins that form intermediate filament cytoskeletons in epithelial cells. It belongs to the type I keratins, which typically consist of acidic, low molecular weight proteins. KRT34 has a calculated molecular weight of 49 kDa with 436 amino acids . Keratins play crucial roles in maintaining cellular structural integrity, with expression patterns that are highly regulated and tissue-specific. KRT34 is primarily expressed in epithelial tissues and is particularly important in hair follicle development. The keratin family members have highly similar rod domains but show unique expression patterns throughout the epidermis, epithelial cells, and hair follicles, suggesting that small differences in amino acid sequence confer tissue specificity .

How does KRT34 function within the keratin family network?

KRT34 functions within the broader context of keratin proteins that form paired intermediate filaments. Keratins typically function as pairs in the cell, with specific type I and type II keratins interacting to form heterodimers. Based on clustering of gene expression patterns, several established "keratin pairs" include KRT1/KRT10, KRT8/KRT18, KRT5/KRT14, KRT6/KRT16, and KRT6/KRT17 . Although the specific pairing pattern for KRT34 is not explicitly stated in the search results, research using the Genotype-Tissue Expression (GTEx) project has enabled reconstruction of tissue-specific keratin expression throughout the human body, providing insights into these pairing relationships. Interestingly, the search results indicate that keratin proteins can become dispensable in some species while being repurposed in others, suggesting evolutionary adaptability in the keratin network .

What types of KRT34 antibodies are available for research applications?

Multiple types of KRT34 antibodies are available for research, varying in host species, clonality, and target epitopes:

The choice depends on the specific experimental application, with polyclonal antibodies offering broader epitope recognition and monoclonal antibodies providing higher specificity for a single epitope .

How should I validate a KRT34 antibody for my specific application?

Thorough validation of KRT34 antibodies is essential for reliable research outcomes. For proper validation:

• Positive control selection: Use samples known to express KRT34, such as HeLa cells, A375 cells, A431 cells, HepG2 cells, L02 cells, or mouse skin tissue, which have been documented to show positive Western blot results with anti-KRT34 antibodies .

• Application-specific validation: Test the antibody in the specific application you intend to use:

  • For Western blotting: Look for a band at approximately 49 kDa, the observed molecular weight of KRT34 .

  • For IHC: Human skin cancer tissue and human lung squamous cell carcinoma tissue have shown positive results .

  • For IF/ICC: HepG2 cells work as positive controls .

• Negative controls: Include samples where KRT34 is not expressed or use isotype controls to confirm specificity.

• Cross-reactivity assessment: Most KRT34 antibodies show reactivity with human samples, with some also recognizing mouse and rat samples . Confirm the species cross-reactivity is appropriate for your research.

• Blocking peptide experiments: Consider using blocking peptides where available to confirm specificity of binding .

What are the optimal protocols for KRT34 detection in different applications?

Western Blotting (WB):

• Recommended dilution: 1:500-1:1000

• Expected molecular weight: 49 kDa

• Sample preparation: Standard protein extraction from tissues or cell lines with protease inhibitors

• Loading controls: Typical housekeeping proteins (β-actin, GAPDH)

Immunohistochemistry (IHC):

• Recommended dilution: 1:50-1:500

• Antigen retrieval: TE buffer pH 9.0 is suggested; alternatively, citrate buffer pH 6.0

• Positive control tissues: Human skin cancer tissue, human lung squamous cell carcinoma tissue

• Detection systems: Standard HRP-DAB or fluorescent secondary antibody systems

Immunofluorescence (IF)/Immunocytochemistry (ICC):

• Recommended dilution: 1:50-1:500

• Sample preparation: PFA fixation with Triton X-100 permeabilization has been successfully used for U-2 OS cells

• Positive control cells: HepG2 cells, U-2 OS cells

ELISA:

• Dilution should be optimized for each specific assay format

• Recombinant protein standards can be used for quantification

For all applications, it is recommended that optimal working dilutions should be determined empirically by the investigator for each specific experimental setup .

How can I troubleshoot common issues in KRT34 antibody staining?

Western Blotting Issues:

• No signal or weak signal:

  • Increase antibody concentration

  • Extend primary antibody incubation time (overnight at 4°C)

  • Ensure proper sample preparation with protease inhibitors

  • Check if your sample expresses KRT34 (HeLa, A375, A431, HepG2, L02 cells, or mouse skin tissue are known positive samples)

• Multiple bands:

  • Increase blocking time or blocking agent concentration

  • Reduce primary antibody concentration

  • Verify antibody specificity with positive controls

  • Consider potential post-translational modifications or splice variants

IHC/IF Troubleshooting:

• High background:

  • Optimize blocking conditions (5% BSA or normal serum)

  • Reduce primary antibody concentration

  • Extend washing steps

• No or weak staining:

  • Optimize antigen retrieval (try both TE buffer pH 9.0 and citrate buffer pH 6.0)

  • Increase antibody concentration within recommended range

  • Extend primary antibody incubation time

  • Use signal amplification systems

• Non-specific staining:

  • Include appropriate negative controls

  • Reduce antibody concentration

  • Ensure proper blocking of endogenous peroxidase activity (for IHC)

When troubleshooting, always compare your results with established positive controls and reference images from suppliers. For instance, paraffin-embedded human hair has been successfully stained for K34 using Abcam's antibody at 1/500 dilution .

How does KRT34 expression pattern differ across tissue types and what are the implications?

KRT34 is predominantly expressed in:

• Skin epithelial tissues

• Hair follicles

• Some specific cancer types, including skin cancer and lung squamous cell carcinoma

The tissue-specific expression pattern of KRT34 suggests that it plays specialized roles in these tissues. Importantly, even small differences in amino acid sequences among keratins can confer highly specific tissue-type functionality. Crystallographic data supports this notion, showing that unique amino acids belonging to keratin interaction pairs are primarily positioned along the outer edges of the coiled-coil rod domain to maximize the diversity of surface chemistry of the intermediate filament .

Understanding these expression patterns has important implications for using KRT34 as a biomarker in diagnostic pathology, particularly in distinguishing different types of epithelial tumors and in studying hair follicle disorders.

What is known about KRT34 evolutionary conservation and species differences?

KRT34 shows interesting evolutionary patterns with notable species-specific differences:

• Cross-species conservation: While KRT34 is present in humans, its conservation across species is variable. The search results indicate that antibodies against human KRT34 can cross-react with mouse KRT34, suggesting some degree of conservation between these species .

• Species-specific absences: Interestingly, entire keratin genes can be absent in certain species. For example, while not specifically mentioned for KRT34, the search results note that KRT3, KRT37, KRT38, and KRT6C are absent from the mouse genome compared to humans . This pattern suggests that some keratins, while important in one species, may become dispensable in others.

• Evolutionary "repurposing": The search results provide a fascinating example with cetaceans (whales, dolphins, porpoises), which lack expression of KRT24. In its absence, the putative partners of KRT24 (i.e., KRT3 and KRT5) interact with KRT14 and KRT12 instead. This observation indicates that "keratin proteins can become dispensable in some species, while being repurposed in others" .

• Genomic organization: The keratin gene family shows distinctive genomic organization. In mice, for example, the type II keratin subgroup of 26 genes is located entirely on chromosome 15, while 27 out of 28 type I keratin genes are on chromosome 11. Similar to humans, the one exception is the type I Krt18 gene, which is located within the type II cluster, suggesting this arrangement predates the human-mouse split .

These evolutionary patterns provide valuable insights into the functional importance and adaptability of different keratins across species, which has implications for the selection of appropriate model organisms for KRT34 research.

What is the role of KRT34 protein interactions in disease mechanisms?

KRT34, like other keratins, participates in protein-protein interactions that can influence disease development and progression. The search results specifically mention that "Protein interactions with K34 such as HP1 and chromatin assembly factors can influence how these diseases develop or progress due to their role in maintaining proper chromatin structure and function" . This suggests KRT34 may have nuclear roles beyond its cytoskeletal functions.

The paired nature of keratin filaments means that disruptions in KRT34 function could also affect its binding partners. As noted in the search results, when certain keratins are absent (as with KRT24 in cetaceans), their binding partners can interact with alternative keratins . This adaptability suggests a complex network of interactions that, when disrupted, could contribute to disease mechanisms.

Understanding these protein interactions is crucial for:

• Identifying potential therapeutic targets

• Developing diagnostic markers

• Understanding the molecular basis of diseases involving keratin dysfunction

• Predicting the effects of specific mutations on keratin function

What controls are essential for validating results with KRT34 antibodies?

Rigorous controls are crucial for ensuring reliable results when working with KRT34 antibodies:

Positive Controls:

• Tissue/cell controls: Include samples known to express KRT34

  • Western blot: HeLa cells, A375 cells, A431 cells, HepG2 cells, L02 cells, mouse skin tissue

  • IHC: Human skin cancer tissue, human lung squamous cell carcinoma tissue

  • IF/ICC: HepG2 cells , U-2 OS cells

• Recombinant protein: Use purified recombinant KRT34 protein as a positive control, especially for antibodies raised against recombinant fragments

Negative Controls:

• Isotype controls: Use non-specific antibodies of the same isotype and host species (e.g., Rabbit IgG for rabbit polyclonal antibodies)

• Tissues/cells lacking KRT34: Include samples known not to express KRT34

• Blocking peptide controls: Pre-incubate the antibody with its specific immunogenic peptide to confirm binding specificity

• Secondary antibody-only controls: Omit primary antibody to assess non-specific binding of secondary antibodies

Additional Validation Controls:

• Knockdown/knockout controls: When possible, use KRT34 knockdown or knockout samples to confirm antibody specificity

• Cross-reactivity controls: If working across species, include samples from each species to verify cross-reactivity

• Concentration gradient: Test a range of antibody concentrations to optimize signal-to-noise ratio

• Method-specific controls: Include controls specific to each application (e.g., loading controls for Western blot, nuclear counterstains for IHC/IF)

Proper implementation of these controls will significantly enhance the reliability and reproducibility of results obtained with KRT34 antibodies.

How should I design experiments to investigate KRT34 expression in different physiological or pathological conditions?

Experimental Design Principles:

• Comparative analysis approach:

  • Include matched normal and disease tissues/cells

  • Consider temporal dynamics (time course experiments)

  • Include relevant biological and technical replicates

• Multi-method validation:

  • Combine protein detection methods (WB, IHC, IF) with mRNA analysis (qPCR, RNA-seq)

  • Use multiple antibodies targeting different epitopes of KRT34

  • Validate key findings with functional assays

• Context-specific considerations:

  • For cancer studies: Compare expression across tumor grades/stages

  • For developmental studies: Analyze expression across different time points

  • For tissue specificity: Use tissue microarrays for broad screening

Suggested Experimental Workflows:

For tissue expression profiling:

• Start with IHC screening on tissue microarrays (1:50-1:500 dilution)

• Confirm findings with Western blot on tissue lysates (1:500-1:1000 dilution)

• Perform co-localization studies using IF with other keratin markers

• Validate protein findings with mRNA analysis

For disease association studies:

• Compare KRT34 expression in matched normal vs. disease samples

• Correlate expression with clinical parameters and outcomes

• Investigate potential mechanisms through co-immunoprecipitation with known interaction partners

• Perform functional studies to assess the impact of altered KRT34 expression

For cell culture manipulations:

• Establish baseline KRT34 expression in your cell model

• Use overexpression or knockdown approaches to modulate KRT34 levels

• Assess phenotypic changes (morphology, proliferation, differentiation)

• Investigate downstream molecular changes through proteomic or transcriptomic approaches

When designing these experiments, consider that KRT34 expression is highly tissue-specific, and its function may vary across different contexts. The antibody dilution should be optimized for each specific application and sample type, as recommended in the search results .

How should I interpret conflicting results when using different KRT34 antibodies?

Conflicting results when using different KRT34 antibodies can arise from several factors. To properly interpret such discrepancies:

• Consider epitope differences:

  • Different antibodies target different regions of KRT34 (e.g., aa362-411 , aa337-436 , aa400-C-terminus )

  • Epitope accessibility may vary by technique and sample preparation

  • Post-translational modifications may mask specific epitopes

  • Action: Map the epitopes of your antibodies and determine if structural differences or modifications could explain the discrepancies

• Evaluate antibody characteristics:

  • Polyclonal antibodies (like those from Proteintech , LifeSpan , and Abcam ) recognize multiple epitopes and may show broader reactivity

  • Monoclonal antibodies (like ABIN517413 ) target a single epitope with higher specificity

  • Action: Prioritize results from monoclonal antibodies for specificity or use consensus findings from multiple antibodies

• Compare methodology differences:

  • Sample preparation variations (fixation methods, buffers, detergents)

  • Protocol differences (blocking agents, incubation times, detection systems)

  • Action: Standardize protocols across antibodies or note methodological differences as potential sources of variation

• Perform validation experiments:

  • Use positive and negative controls with each antibody

  • Verify with orthogonal techniques (e.g., mRNA analysis)

  • Consider antibody validation using KRT34 knockdown/knockout models

  • Action: Design experiments that specifically address the discrepancy

• Biological interpretations:

  • Different antibodies may detect different isoforms or splice variants

  • Results may reflect true biological variability in KRT34 expression or localization

  • Action: Consider if the conflicting results reveal previously unknown aspects of KRT34 biology

When reporting conflicting results, transparently document all antibodies used (including catalog numbers), detailed methodologies, and consider presenting both concordant and discordant findings as they may collectively provide more comprehensive insights into KRT34 biology.

What quantitative approaches are recommended for analyzing KRT34 expression patterns?

Western Blot Quantification:

• Densitometric analysis using software like ImageJ, normalizing to loading controls

• Use of standard curves with recombinant KRT34 protein for absolute quantification

• Comparison to housekeeping proteins (β-actin, GAPDH) for relative quantification

• Statistical analysis across multiple biological replicates (minimum n=3)

Immunohistochemistry Quantification:

• H-score method: combines staining intensity and percentage of positive cells

• Digital pathology approaches using whole slide imaging and analysis software

• Tissue microarray analysis for high-throughput comparison across multiple samples

• Machine learning-based image analysis for unbiased quantification

Immunofluorescence Quantification:

• Mean fluorescence intensity measurements

• Co-localization analysis with other markers using Pearson's or Mander's coefficients

• Subcellular distribution analysis using line scan profiles

• 3D reconstruction for spatial distribution analysis

Multi-omics Integration:

• Correlation of protein expression (antibody-based) with mRNA expression (qPCR, RNA-seq)

• Integration with other keratin family members for network analysis

• Correlation with clinical parameters in disease studies

• Single-cell analysis to assess expression heterogeneity

When quantifying KRT34 expression, it's important to:

• Include appropriate positive controls (e.g., HeLa cells, HepG2 cells)

• Establish background threshold using negative controls

• Perform statistical validation of quantitative differences

• Consider the context of total keratin expression, as keratins function in pairs and networks

The choice of quantification method should align with your research question. For example, tissue-wide expression patterns might be best analyzed through digital pathology approaches, while specific cellular mechanisms might require high-resolution immunofluorescence quantification with co-localization analysis.

What are the latest techniques for studying KRT34 interactions and functions?

Recent advances have expanded the toolkit for investigating KRT34 biology:

• Proximity labeling techniques:

  • BioID or TurboID fusion proteins to identify proximal interacting partners of KRT34

  • APEX2-based proximity labeling for temporal interaction studies

  • These approaches can reveal novel protein interactions with KRT34, including transient associations

• High-resolution imaging approaches:

  • Super-resolution microscopy (STORM, PALM, SIM) to visualize keratin filament ultrastructure

  • Live-cell imaging with fluorescently tagged KRT34 to monitor dynamics

  • Correlative light and electron microscopy (CLEM) to link KRT34 localization with ultrastructural features

• Functional genomics tools:

  • CRISPR-Cas9 genome editing for precise KRT34 knockout or mutation

  • RNA interference for transient knockdown studies

  • CRISPRi/CRISPRa for modulation of KRT34 expression without altering the genome

• Protein-protein interaction analysis:

  • Hydrogen-deuterium exchange mass spectrometry (HDX-MS) to map interaction interfaces

  • Förster resonance energy transfer (FRET) to study interactions in living cells

  • Co-immunoprecipitation coupled with mass spectrometry to identify interaction partners

• Single-cell analysis approaches:

  • Single-cell RNA-seq to profile KRT34 expression heterogeneity

  • Single-cell proteomics to correlate KRT34 with broader protein expression patterns

  • Spatial transcriptomics to map KRT34 expression within tissue architecture

These emerging techniques can provide insights into how KRT34 interacts with proteins like HP1 and chromatin assembly factors, which are mentioned in the search results as potentially influencing disease development through their role in maintaining proper chromatin structure and function .

How does understanding KRT34 genomic organization contribute to research on keratin-related diseases?

The genomic organization of KRT34 and other keratin genes provides important context for understanding keratin-related diseases:

• Clustered gene arrangement: Keratin genes are organized in clusters on chromosomes. In mice, the type II keratin subgroup is located entirely on chromosome 15, while most type I keratin genes (including the equivalent of human KRT34) are on chromosome 11 . This clustered arrangement suggests coordinated regulation and potential for large-scale genomic events affecting multiple keratin genes simultaneously.

• Evolutionary insights: The search results indicate that all mouse keratin type I and type II genes are syntenic with their human orthologs . This conservation suggests functional importance and provides validation for using mouse models to study keratin-related human diseases.

• Disease mechanisms: The ClinVar database currently lists 26 human disease-causing variants within various domains of keratin proteins . Understanding the genomic organization can help interpret these variants in the context of:

  • Potential regulatory region disruptions

  • Copy number variations affecting multiple keratin genes

  • Implications of variants in highly conserved vs. variable regions

• Tissue-specific expression regulation: The clustered arrangement may facilitate coordinated tissue-specific expression through shared enhancers or chromatin domains. This has implications for understanding diseases affecting specific epithelia.

• Evolutionary adaptability: The search results note that keratins can become "dispensable in some species, while being repurposed in others" . This evolutionary flexibility may inform our understanding of human variation in keratin expression and function.

For researchers studying keratin-related diseases, this genomic context suggests several approaches:

• Analyzing the extended genomic region around KRT34 when interpreting disease variants

• Considering the impact of variants on coordinated expression with other keratins

• Exploring conserved non-coding regions that may regulate multiple keratin genes

• Investigating potential compensatory mechanisms from other keratin family members when KRT34 function is compromised

The genomic organization thus provides a framework for interpreting disease mechanisms beyond simple protein structure-function relationships.